Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Receivables - Net (2016 - 2025)

Historic Receivables - Net for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to $66.2 million.

  • Akebia Therapeutics' Receivables - Net rose 10585.33% to $66.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $66.2 million, marking a year-over-year increase of 10585.33%. This contributed to the annual value of $34.4 million for FY2024, which is 1252.74% down from last year.
  • Latest data reveals that Akebia Therapeutics reported Receivables - Net of $66.2 million as of Q3 2025, which was up 10585.33% from $72.8 million recorded in Q2 2025.
  • Akebia Therapeutics' Receivables - Net's 5-year high stood at $82.0 million during Q2 2022, with a 5-year trough of $18.7 million in Q1 2023.
  • For the 5-year period, Akebia Therapeutics' Receivables - Net averaged around $42.4 million, with its median value being $35.2 million (2021).
  • In the last 5 years, Akebia Therapeutics' Receivables - Net soared by 726871.43% in 2021 and then tumbled by 7613.23% in 2023.
  • Over the past 5 years, Akebia Therapeutics' Receivables - Net (Quarter) stood at $51.6 million in 2021, then decreased by 21.9% to $40.3 million in 2022, then dropped by 2.47% to $39.3 million in 2023, then fell by 12.53% to $34.4 million in 2024, then skyrocketed by 92.69% to $66.2 million in 2025.
  • Its last three reported values are $66.2 million in Q3 2025, $72.8 million for Q2 2025, and $61.5 million during Q1 2025.